Millennium Management
VC Fund
New York, United States
Millennium Management is a multi-strategy investment firm and pursues a diverse array of investment strategies across industry sectors. It is a global alternative investment management firm, founded in 1989, which manages more than $56.3 billion in assets.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 6%
Last updated:
For AI agents: llms.txt
Industries Millennium Management invests in
Stages Millennium Management invests in
Countries Millennium Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniel Elbaz
|
|||
Dennis Chao
|
|||
Jeffrey Verschleiser
|
|||
Lloyd Satchwell
|
Investment Focus
Industry
- Health Care 6 (33%)
- Biotechnology 5 (28%)
- FinTech 3 (17%)
- Medical 3 (17%)
- Artificial Intelligence 3 (17%)
Stage
- Series D 3 (17%)
- Post-IPO Equity 3 (17%)
- Series B 2 (11%)
- Series F 2 (11%)
- Series A 1 (6%)
Country
- United States 8 (44%)
- United Kingdom 2 (11%)
- China 1 (6%)
- India 1 (6%)
- South Korea 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Daniel Elbaz
Senior Quantitative Researcher
|
Senior Quantitative Researcher | Total investments: 0 | Find email | |
|
Dennis Chao
Analyst
|
Analyst | Total investments: 0 | Find email | |
Hunter Merghart
COO, Digital Assets
|
COO, Digital Assets | Total investments: 0 | Find email | |
|
Jeffrey Verschleiser
Global Head of Credit/Mortgage Backed Securities Risk Management
|
Global Head of Credit/Mortgage Backed Securities Risk Management | Total investments: 0 | Find email | |
|
Lloyd Satchwell
Quantitative Trading
|
Quantitative Trading | Total investments: 0 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Caris Life Sciences
|
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology. The company offers a comprehensive tumor profiling service known as Caris Molecular Intelligence, which analyzes DNA, RNA, and proteins to help oncologists identify potential treatment options. Caris also operates a platform calledCaris CODEai that integrates molecular data with clinical outcomes to support research and drug development. Its services cater to biopharma partners, healthcare providers, and academic institutions aiming to improve cancer diagnostics and therapy selection. The company incorporates machine learning models to discover new biomarkers and therapeutic targets based on large-scale multi-omic data. | $168M / Private Equity / Apr 07, 2025 | |
Cardurion Pharmaceuticals
|
Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. | $260M / Series B / Jul 16, 2024 | |
Carmot Therapeutics
|
Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California. | $150M / Series E / May 25, 2023 | |
One97 Communications
|
One97 delivers mobile content and commerce services to millions of mobile consumers through India’s most widely deployed telecom applications cloud platform. It has more than 4,500 employees with its headquarters in New Delhi and regional offices in Mumbai, Bengaluru, Pune, Chennai, and Kolkata with global presence in Africa, Europe, Middle East,and Southeast Asia. Marquee investors like Alibaba Group, Ant Financial (AliPay), SAIF Partners, Mediatek, Sapphire Venture, and Silicon Valley Bank back it. | $200M / Post-IPO Secondary / Nov 17, 2022 | |
Metagenomi
|
Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $175M / Series B / Jan 25, 2022 | |
Himachal Futuristic Communications Limited
|
HFCL, The Company specializes in manufacturing of telecommunication equipment. | $78.9M / Post-IPO Equity / Dec 14, 2021 | |
Palladyne AI
|
Sarcos is a wearable and teleoperated industrial robotics company that augments humans to enhance productivity and safety.Sarcos Robotics augments human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Leveraging more than 30years of research and development, Sarcos’ mobile robotic systems, including the Guardian® S, Guardian® GT, and Guardian® XO®, are revolutionizing the future of work wherever physically demanding work is done. Formerly the robotics division of a major defense contractor, Sarcos is based in Salt Lake City, Utah, powered by an innovative team of entrepreneurs and engineers. | $220M / Post-IPO Equity / Sep 27, 2021 | |
Market Kurly
|
Market Kurly is an online premium grocery service that compares quality and price when looking for good ingredients for foreign goodies.Market Kurly is a food delivery and logistics platform that enables users to order food via the website and receive it the following morning. The company delivers fresh high-end desserts, bread, milk, bottledwater, condiments such as flour & salt, processed foods, and more.The company was founded in 2015 and based in Seoul, South Korea. | $200M / Series F / Jul 09, 2021 | |
|
Market Kurly
|
Market Kurly is an online premium grocery service that compares quality and price when looking for good ingredients for foreign goodies.Market Kurly is a food delivery and logistics platform that enables users to order food via the website and receive it the following morning. The company delivers fresh high-end desserts, bread, milk, bottledwater, condiments such as flour & salt, processed foods, and more.The company was founded in 2015 and based in Seoul, South Korea. | $196.8M / Series F / Jul 09, 2021 | |
Payoneer
|
Payoneer is a financial technology company that enables small and medium-sized enterprises to transact and thrive. | $300M / Post-IPO Equity / Jun 28, 2021 | |
| See all 18 investments → | |||
Co-Investors
BlackRock
4 deals together
Coatue
4 deals together
First Light Asset Management
4 deals together
T. Rowe Price
4 deals together
ClearBridge Investments
3 deals together
Fidelity
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Millennium Management invest in?
Millennium Management invests primarily in Health Care, Biotechnology and FinTech startups, most often at Series D and Post-IPO Equity stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Millennium Management?
Public channels for Millennium Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Millennium Management?
The team at Millennium Management includes Daniel Elbaz (Senior Quantitative Researcher), Dennis Chao (Analyst) and Hunter Merghart (COO, Digital Assets), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
